A recent study suggests that the timing of cancer treatments might influence their effectiveness. According to research published in Cancer, the journal of the American Cancer Society, patients with extensive-stage small cell lung cancer (ES-SCLC) who received immunochemotherapy in the morning had better outcomes than those treated later in the day.
The study was conducted by a team at the Affiliated Cancer Hospital of Xiangya School of Medicine in China. They analyzed data from nearly 400 patients treated between May 2019 and October 2023. All participants received first-line immunotherapy, either atezolizumab or durvalumab, alongside chemotherapy.
Dr. Yongchang Zhang, the lead author and chief director at the Hunan Cancer Hospital in Changsha, explained that patients receiving treatment before 3:00 PM had a 52% lower risk of cancer progression and a 63% lower risk of death compared to those treated later. The findings were surprising, highlighting how simply adjusting treatment times could lead to significant benefits.
This research aligns with the concept of chronotherapy, which explores how our body’s natural rhythms may affect immune responses and the effectiveness of medications. Essentially, cancer treatments may produce better results at certain times due to variations in immune activity over the course of the day.
Dr. Zhang recommended that immunotherapy should be scheduled in the early morning. Previous studies on other types of cancer have shown similar patterns, suggesting that overall survival rates improve when treatments occur earlier in the day.
Dr. Gilberto Lopes from the Sylvester Comprehensive Cancer Center at the University of Miami noted that this study supports prior findings indicating that the immune system’s response to treatment can be influenced by the timing of administration, particularly in challenging cases like small cell lung cancer.
While the study’s findings are promising, it does have limitations. Since it was observational, it cannot definitively establish a cause-and-effect relationship between treatment timing and patient outcomes. Other factors, such as the quality of life or socioeconomic status of patients treated in the morning, could also play a role in these results.
Looking forward, researchers plan to conduct randomized trials to further investigate these findings and determine the optimal timing for treatments based on individual patient factors. Dr. Lopes emphasized that while these results are exciting, patients shouldn’t panic about their treatment schedules; rather, the study encourages a reevaluation of the time aspect in treatment planning.
